Study of prostate cancer spread using biopsy and lab tests
Part of Cancer, Kidney & urinary clinical trials.
This trial studies the “microenvironment” around prostate cancer metastases, using specimens taken during biopsy and other scans. It may help researchers understand what drives prostate cancer spread and improve future treatment choices.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can read and sign an informed consent form in writing, and you’re able to understand the study.
- You are age 18 or older.
- Your doctor says your daily activity level is good to moderate (ECOG 0–2).
- You have prostate adenocarcinoma (or a strong clinical picture of prostate cancer with typical PSA and spread).
- Your cancer has spread to lymph nodes or other body sites (N1 or M1) based on scan results like CT/MRI, bone scan, or PET.
- Your blood counts and clotting tests are strong enough for a biopsy (enough hemoglobin, platelets, and safe PT/INR and PTT).
- You can have a core needle biopsy with at least 21-gauge needle cores about 5 mm deep, and the doctor can safely collect roughly 3–8 samples.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a type of high-precision radiation (MDRT) to standard hormone therapy works better for men with prostate cancer that has spread to just a few places. It is for patients who are newly diagnosed and on long-term hormone therapy.
This trial collects tumor samples from men with prostate cancer to study the bacteria and other microbes inside the tumor. It aims to learn how these microbes might affect the cancer and treatment.
This study is looking at how prostate cancer that has spread changes over time, especially in terms of the immune system. It uses advanced tissue analysis to understand the disease better.
This Phase 3 trial tests whether treating only a small number of prostate cancer metastases can help people with “oligorecurrent” (limited repeat) prostate cancer. It may reduce cancer activity while avoiding broader whole-body treatment for some patients.
This trial enrolls adults who are being evaluated or treated for possible or confirmed prostate cancer and allows researchers to collect prostate tissue. It may help improve understanding of prostate cancer over the course of diagnosis and standard care.
This study follows men with advanced prostate cancer that has spread to other parts of the body. It aims to learn more about how the disease and treatments affect patients over time, so doctors can improve care.
Hear when a new Recurrent Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.